Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

被引:806
作者
Maughan, Timothy S. [2 ]
Adams, Richard A. [2 ]
Smith, Christopher G. [2 ]
Meade, Angela M. [1 ]
Seymour, Matthew T. [3 ,4 ]
Wilson, Richard H. [8 ]
Idziaszczyk, Shelley [2 ]
Harris, Rebecca [2 ]
Fisher, David [1 ]
Kenny, Sarah L. [1 ]
Kay, Edward [1 ]
Mitchell, Jenna K. [1 ]
Madi, Ayman [2 ]
Jasani, Bharat [2 ]
James, Michelle D. [2 ]
Bridgewater, John [5 ]
Kennedy, M. John [6 ]
Claes, Bart [7 ]
Lambrechts, Diether [7 ]
Kaplan, Richard [1 ]
Cheadle, Jeremy P. [2 ]
机构
[1] MRC Clin Trials Unit, London NW1 2DA, England
[2] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[3] St James Univ Hosp, Leeds, W Yorkshire, England
[4] Univ Leeds, Leeds, W Yorkshire, England
[5] UCL, Inst Canc, London, England
[6] All Ireland Cooperat Oncol Res Grp, ICORG, Dublin, Ireland
[7] Univ Louvain, VIB, Vesalius Res Ctr, Louvain, Belgium
[8] Queens Univ Belfast, Belfast, Antrim, North Ireland
基金
英国医学研究理事会;
关键词
GROWTH-FACTOR RECEPTOR; MUTATION STATUS; LUNG-CANCER; PANITUMUMAB; KRAS; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN; GEFITINIB; SURVIVAL;
D O I
10.1016/S0140-6736(11)60613-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. Methods In this randomised controlled trial, patients who were fit for but had not received previous chemotherapy for advanced colorectal cancer were randomly assigned to oxaliplatin and fluoropyrimidine chemotherapy (arm A), the same combination plus cetuximab (arm B), or intermittent chemotherapy (arm C). The choice of fluoropyrimidine therapy (capecitabine or infused fluouroracil plus leucovorin) was decided before randomisation. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not masked. The comparison of arms A and C is described in a companion paper. Here, we present the comparison of arm A and B, for which the primary outcome was overall survival in patients with KRAS wild-type tumours. Analysis was by intention to treat. Further analyses with respect to NRAS, BRAF, and EGFR status were done. The trial is registered, ISRCTN27286448. Findings 1630 patients were randomly assigned to treatment groups (815 to standard therapy and 815 to addition of cetuximab). Tumour samples from 1316 (81%) patients were used for somatic molecular analyses; 565 (43%) had KRAS mutations. In patients with KRAS wild-type tumours (arm A, n=367; arm B, n=362), overall survival did not differ between treatment groups (median survival 17.9 months [IQR 10-3-29.2] in the control group vs 17.0 months [9.4-30.1] in the cetuximab group; HR 1.04, 95% CI 0.87-1.23, p=0.67). Similarly, there was no effect on progression-free survival (8.6 months [IQR 5.0-12.5] in the control group vs 8.6 months [5.1-13-8] in the cetuximab group; HR 0-96, 0.82-1.12, p=0-60). Overall response rate increased from 57% (n=209) with chemotherapy alone to 64% (n=232) with addition of cetuximab (p=0.049). Grade 3 and higher skin and gastrointestinal toxic effects were increased with cetuximab (14 vs 114 and 67 vs 97 patients in the control group vs the cetuximab group with KRAS wild-type tumours, respectively). Overall survival differs by somatic mutation status irrespective of treatment received: BRAF mutant, 8.8 months (IQR 4.5-27.4); KRAS mutant, 14.4 months (8.5-24.0); all wild-type, 20.1 months (11.5-31.7). Interpretation This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-fine chemotherapy in patients with widespread metastases cannot be recommended.
引用
收藏
页码:2103 / 2114
页数:12
相关论文
共 50 条
[31]   Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis [J].
Park, Hanla A. ;
Edelmann, Dominic ;
Canzian, Federico ;
Harrison, Tabitha A. ;
Hua, Xinwei ;
Shi, Qian ;
Silverman, Allison ;
Schneider, Martin ;
Goldberg, Richard M. ;
Alberts, Steven R. ;
Hoffmeister, Michael ;
Brenner, Hermann ;
Chan, Andrew T. ;
Peters, Ulrike ;
Newcomb, Polly A. ;
Chang-Claude, Jenny .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (11) :2087-2091
[32]   Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy [J].
Mizushima, Tsunekazu ;
Fukunaga, Mutsumi ;
Sueda, Toshinori ;
Ikeda, Masataka ;
Kato, Takeshi ;
Kim, Ho Min ;
Kudo, Toshihiro ;
Murata, Kohei ;
Nishimura, Junichi ;
Hata, Taishi ;
Matsuda, Chu ;
Yamamoto, Hirofumi ;
Doki, Yuichiro ;
Mori, Masaki .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (01) :81-90
[33]   A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study [J].
Sato, Yasushi ;
Hirakawa, Masahiro ;
Ohnuma, Hiroyuki ;
Takahashi, Minoru ;
Okamoto, Tetsuro ;
Okamoto, Koichi ;
Miyamoto, Hiroshi ;
Muguruma, Naoki ;
Furuhata, Tomohisa ;
Takemasa, Ichiro ;
Kato, Junji ;
Takayama, Tetsuji .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) :1133-1139
[34]   A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer [J].
Xiong, Jian Ping ;
Zhang, Ling ;
Zhong, Lu Xing ;
Qiu, Feng ;
Xu, Jun ;
Tao, Qing Song ;
Xiang, Xiao Jun ;
Yu, Feng ;
Tang, Xiao Mei .
ANTI-CANCER DRUGS, 2007, 18 (09) :1103-1107
[35]   Cetuximab or BevacizumabWith First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same [J].
Lieu, Christopher H. ;
Messersmith, Wells A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23) :2376-2378
[36]   Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer [J].
Yoshito Komatsu ;
Chikashi Ishioka ;
Ken Shimada ;
Yasuhide Yamada ;
Makio Gamoh ;
Atsushi Sato ;
Tatsuro Yamaguchi ;
Satoshi Yuki ;
Satoshi Morita ;
Shin Takahashi ;
Rei Goto ;
Minoru Kurihara .
BMC Cancer, 15
[37]   Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial [J].
Wang, Huijuan ;
Huang, Lingfei ;
Gao, Peng ;
Zhu, Zhengyi ;
Ye, Weifeng ;
Ding, Haiying ;
Fang, Luo .
BMJ OPEN, 2020, 10 (02)
[38]   Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping [J].
Papaxoinis, George ;
Kotoula, Vassiliki ;
Giannoulatou, Eleni ;
Koliou, Georgia-Angeliki ;
Karavasilis, Vasilios ;
Lakis, Sotirios ;
Koureas, Andreas ;
Bobos, Mattheos ;
Chalaralambous, Elpida ;
Daskalaki, Emily ;
Chatzopoulos, Kyriakos ;
Tsironis, George ;
Pazarli, Elisavet ;
Chrisafi, Sofia ;
Samantas, Epaminontas ;
Kaklamanos, Ioannis G. ;
Varthalitis, Ioannis ;
Konstantara, Athina ;
Syrigos, Konstantinos N. ;
Pentheroudakis, George ;
Pectasides, Dimitrios ;
Fountzilas, George .
MEDICAL ONCOLOGY, 2018, 35 (07)
[39]   Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC [J].
Andric, Zoran ;
Galffy, Gabriella ;
Dols, Manuel Cobo ;
Szima, Barna ;
Stojanovic, Goran ;
Petrovic, Marina ;
Felip, Enriqueta ;
Baz, David Vicente ;
Aix, Santiago Ponce ;
Juan-Vidal, Oscar ;
Szalai, Zsuzsanna ;
Losonczy, Gyorgy ;
Blanco, Antonio Calles ;
Bernabe, Reyes ;
Ledo, Gema Garcia ;
Hernandez, Andres Aguilar ;
Duecker, Klaus ;
Zhou, Dongli ;
Schroeder, Andreas ;
Guezel, Guelseren ;
Ciardiello, Fortunato .
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02)
[40]   Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer [J].
Whyte, S. ;
Pandor, A. ;
Stevenson, M. ;
Rees, A. .
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 :47-53